Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Susan Branford, Carol Wadham, Naranie Shanmuganathan, Adelina Fernandes, Nur Hezrin Shahrin, Jinghua Feng, John Toubia, Paul Wang, Chung Hoow Kok, Muneeza Maqsood, Verity Saunders, Rob King, Ming Lin, Rosalie Kenyon, Ilaria Stefania Pagani, David T Yeung, David M. Ross, Agnes S. M. Yong, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 447.

https://doi.org/10.1182/blood-2023-174425

Published: 2023

Journal Articles

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Naranie Shanmuganathan, David T Yeung, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, David M Ross, Andreas W Schreiber, Timothy Hughes, Susan Branford

Blood (2022) 140 (Supplement 1): 805–806.

https://doi.org/10.1182/blood-2022-158743

Published: 2022

Journal Articles

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Susan Branford, Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Andreas W Schreiber, Chung Hoow Kok, Verity A Saunders, Rob King, Ming Lin, Ilaria S Pagani, David T Yeung, David M Ross, Agnes S.M. Yong, Timothy Hughes

Blood (2022) 140 (Supplement 1): 3916–3917.

https://doi.org/10.1182/blood-2022-158735

Published: 2022

Journal Articles

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

Naranie Shanmuganathan, FRACP,FRCPA,MBBS, Carol Wadham, PhD, Nur Hezrin Shahrin, PhD, Daniel Thomson, PhD BSc, Jinghua Feng, PhD, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, PhD, David M Ross, MBBS, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Andreas W Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Susan Branford, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136962

Published: 2020

Journal Articles

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Susan Branford, PhD FFSc (RCPA), Carol Wadham, PhD, Naranie Shanmuganathan, MBBS FRACP FRCPA, Daniel Thomson, PhD BSc, NUR Hezrin Shahrin, PhD, Jinghua Feng, PhD, Verity A Saunders, Wendy T Parker, PhD, Rob King, Paul Wang, PhD, Hamish S Scott, PhD FFSc (RCPA), Andreas Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 2918.

https://doi.org/10.1182/blood-2019-123242

Published: 2019

NARROW

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Email alerts

ASH Publications

American Society of Hematology

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only